Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures

Stefan Oscarson, Mia Alpe, Pär Svahnberg, Antonio Nakouzi, Arturo Casadevall

Research output: Contribution to journalArticle

Abstract

Antibodies to the glucuronoxylomannan (GXM) component of the polysaccharide capsule of Cryptococcus neoformans are protective and GXM-protein conjugate vaccines can elicit protective immune responses. We report the synthesis of a heptasaccharide oligosaccharide representing the putative dominant motif of serotype A GXM and demonstrate that it is recognized by some monoclonal antibodies (mAbs) generated to GXM. Conjugation of the heptasaccharide to human serum albumin (HSA) resulted in an immunogenic compound that elicited high-titer IgG responses in mice when given with complete Freund's adjuvant. The antibody response elicited by the oligosaccharide conjugate vaccine had characteristics of a T-cell-dependent response. The availability of an immunogenic oligosaccharide representing a structural motif of GXM will prove useful in studies of antibody epitope specificity and represents a potential synthetic oligosaccharide vaccine against this fungal pathogen.

Original languageEnglish (US)
Pages (from-to)3961-3972
Number of pages12
JournalVaccine
Volume23
Issue number30
DOIs
StatePublished - Jun 10 2005
Externally publishedYes

Fingerprint

glycoconjugates
Cryptococcus neoformans
Glycoconjugates
Oligosaccharides
oligosaccharides
synthesis
Conjugate Vaccines
antibodies
vaccines
Synthetic Vaccines
Antibody Specificity
Freund's Adjuvant
epitopes
adjuvants
monoclonal antibodies
serotypes
polysaccharides
Serum Albumin
T-lymphocytes
immune response

Keywords

  • Antibody
  • Conjugate
  • Cryptococcus
  • Immune response
  • Polysaccharide
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. / Oscarson, Stefan; Alpe, Mia; Svahnberg, Pär; Nakouzi, Antonio; Casadevall, Arturo.

In: Vaccine, Vol. 23, No. 30, 10.06.2005, p. 3961-3972.

Research output: Contribution to journalArticle

Oscarson, Stefan ; Alpe, Mia ; Svahnberg, Pär ; Nakouzi, Antonio ; Casadevall, Arturo. / Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. In: Vaccine. 2005 ; Vol. 23, No. 30. pp. 3961-3972.
@article{0bc9d954f65b4e5b8eb0a6aca83d55ac,
title = "Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures",
abstract = "Antibodies to the glucuronoxylomannan (GXM) component of the polysaccharide capsule of Cryptococcus neoformans are protective and GXM-protein conjugate vaccines can elicit protective immune responses. We report the synthesis of a heptasaccharide oligosaccharide representing the putative dominant motif of serotype A GXM and demonstrate that it is recognized by some monoclonal antibodies (mAbs) generated to GXM. Conjugation of the heptasaccharide to human serum albumin (HSA) resulted in an immunogenic compound that elicited high-titer IgG responses in mice when given with complete Freund's adjuvant. The antibody response elicited by the oligosaccharide conjugate vaccine had characteristics of a T-cell-dependent response. The availability of an immunogenic oligosaccharide representing a structural motif of GXM will prove useful in studies of antibody epitope specificity and represents a potential synthetic oligosaccharide vaccine against this fungal pathogen.",
keywords = "Antibody, Conjugate, Cryptococcus, Immune response, Polysaccharide, Vaccine",
author = "Stefan Oscarson and Mia Alpe and P{\"a}r Svahnberg and Antonio Nakouzi and Arturo Casadevall",
year = "2005",
month = "6",
day = "10",
doi = "10.1016/j.vaccine.2005.02.029",
language = "English (US)",
volume = "23",
pages = "3961--3972",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures

AU - Oscarson, Stefan

AU - Alpe, Mia

AU - Svahnberg, Pär

AU - Nakouzi, Antonio

AU - Casadevall, Arturo

PY - 2005/6/10

Y1 - 2005/6/10

N2 - Antibodies to the glucuronoxylomannan (GXM) component of the polysaccharide capsule of Cryptococcus neoformans are protective and GXM-protein conjugate vaccines can elicit protective immune responses. We report the synthesis of a heptasaccharide oligosaccharide representing the putative dominant motif of serotype A GXM and demonstrate that it is recognized by some monoclonal antibodies (mAbs) generated to GXM. Conjugation of the heptasaccharide to human serum albumin (HSA) resulted in an immunogenic compound that elicited high-titer IgG responses in mice when given with complete Freund's adjuvant. The antibody response elicited by the oligosaccharide conjugate vaccine had characteristics of a T-cell-dependent response. The availability of an immunogenic oligosaccharide representing a structural motif of GXM will prove useful in studies of antibody epitope specificity and represents a potential synthetic oligosaccharide vaccine against this fungal pathogen.

AB - Antibodies to the glucuronoxylomannan (GXM) component of the polysaccharide capsule of Cryptococcus neoformans are protective and GXM-protein conjugate vaccines can elicit protective immune responses. We report the synthesis of a heptasaccharide oligosaccharide representing the putative dominant motif of serotype A GXM and demonstrate that it is recognized by some monoclonal antibodies (mAbs) generated to GXM. Conjugation of the heptasaccharide to human serum albumin (HSA) resulted in an immunogenic compound that elicited high-titer IgG responses in mice when given with complete Freund's adjuvant. The antibody response elicited by the oligosaccharide conjugate vaccine had characteristics of a T-cell-dependent response. The availability of an immunogenic oligosaccharide representing a structural motif of GXM will prove useful in studies of antibody epitope specificity and represents a potential synthetic oligosaccharide vaccine against this fungal pathogen.

KW - Antibody

KW - Conjugate

KW - Cryptococcus

KW - Immune response

KW - Polysaccharide

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=19444383556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444383556&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.02.029

DO - 10.1016/j.vaccine.2005.02.029

M3 - Article

C2 - 15917118

AN - SCOPUS:19444383556

VL - 23

SP - 3961

EP - 3972

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -